Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting Phase 1 / 2 Trials for DB11771 (Tremelimumab)

Also known as: Head and Neck Squamous Cell Carcinoma

IndicationStatusPhase
DBCOND0043665 (Head and Neck Squamous Cell Carcinoma (HNSCC))Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02643303A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible CancersTreatment